UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

November 4, 2020

CHIMERA INVESTMENT CORPORATION

(Exact name of registrant as specified in its charter)

Maryland1-3379626-0630461(State or Other Jurisdiction
of Incorporation)(Commission
File Number)(IRS Employer
Identification No.)

520 Madison Avenue, 32nd Fl

New York New York 10022

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 626-2300

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value \$0.01 per share	CIM	New York Stock Exchange
8.00% Series A Cumulative Redeemable Preferred Stock	CIM PRA	New York Stock Exchange
8.00% Series B Cumulative Fixed-to-Floating Rate Redeemable Preferred Stock	CIM PRB	New York Stock Exchange
7.75% Series C Cumulative Fixed-to-Floating Rate Redeemable Preferred Stock	CIM PRC	New York Stock Exchange
8.00% Series D Cumulative Fixed-to-Floating Rate Redeemable Preferred Stock	CIM PRD	New York Stock Exchange

Registrant's Web site address: www.chimerareit.com

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

On November 4, 2020, the registrant issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this report.

On November 4, 2020, the registrant posted supplemental financial information on the News & Events - Press Releases section of its website (www.chimerareit.com). A copy of the supplemental financial information is furnished as Exhibit 99.2 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

- (d) Exhibits
- 99.1 Press Release, dated November 4, 2020, issued by Chimera Investment Corporation
- 99.2 <u>Supplemental Financial Information for the quarter ended September 30, 2020</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Chimera Investment Corporation

By: <u>/s/ Rob Colligan</u> Name: Rob Colligan

Title: Chief Financial Officer

Date: November 4, 2020



PRESS RELEASE

NYSE: CIM

CHIMERA INVESTMENT CORPORATION 520 Madison Avenue New York, New York 10022

Investor Relations 888-895-6557 www.chimerareit.com

FOR IMMEDIATE RELEASE

CHIMERA INVESTMENT CORPORATION REPORTS 3RD QUARTER 2020 EARNINGS

- GAAP NET INCOME OF \$1.32 PER COMMON SHARE
- CORE EARNINGS⁽¹⁾ OF \$0.33 PER COMMON SHARE
- GAAP BOOK VALUE OF \$11.91 PER COMMON SHARE

NEW YORK - (BUSINESS WIRE) - Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the third quarter ended September 30, 2020. The Company's GAAP net income for the third quarter was \$349 million, or \$1.32 per common share. Core earnings⁽¹⁾ for the third quarter was \$80 million, or \$0.33 per common share.

"Over the past six months we have concentrated the company's efforts on strengthening the balance sheet and protecting our valuable credit assets" said Matthew Lambiase, President and Chief Executive Officer. "These actions contributed to this quarters strong performance and enabled us to complete three securitizations while purchasing \$640 million loans for our portfolio."

(1) Core earnings per adjusted diluted common share is a non-GAAP measure. See additional discussion on page 5.

Other Information

Chimera Investment Corporation is a publicly traded real estate investment trust, or REIT, that is primarily engaged in the business of investing directly or indirectly through our subsidiaries, on a leveraged basis, in a diversified portfolio of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency CMBS, Agency RMBS, and other real estate related securities.

CHIMERA INVESTMENT CORPORATION CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION

(dollars in thousands, except share and per share data) (Unaudited)

Cash and eash equivalents \$ 3.35,717 \$ 109.878 Non-Agency RMBS, at fair value (net of allowance for credit losses of \$167 thousand and \$0 thousand, respectively) \$2,218.289 \$2,614,400,203 Agency CMBS, at fair value \$1,754,740 \$2,850,717 Lours held for investment, at fair value \$1,754,740 \$2,850,717 Lours held for investments sold \$6,8072 \$14,422,815 Receivable for investments sold \$8,672 \$14,622 Cherral seases \$7,5155 \$194,301 Derivatives, at fair value, net \$1,809,868 \$7,118,671 Total assets \$7,5155 \$194,301 Derivatives, at fair value, net \$1,809,868 \$7,118,671 Total assets \$1,809,868 \$7,18,675		September 30, 2020	December 31, 2019
Agency RMBS, at fair value 9,988 6,400,203 Agency CMBS, at fair value 1,754,740 2,850,713 Coans held for investment, at fair value 1,533,222 14,202,813 Receivable for investments sold 6,727 11,612,223 Chromatic receivable 8,672,73 11,612,223 Other assets 75,155 194,010 Chromatic receivable 8,073,68 2,711,810 Derivatives, at fair value, end 8,093,88 3,247,85 Courtised of the fair value, end and \$15.4 billion pledged as collateral, respectively 4,700,037 13,427,55 Securitized debt, collateralized by Non-Agency RMBS (\$228 million and \$398 million pledged as collateral, respectively 4,700,037 8,179,080 Courtized debt, a fair value, collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively 7,0641 -7,041 -8,179,080 Courtized debt, a fair value, collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively 8,179,490 8,179,680 Courtized debt, a fair value, collateralized by loans held for investment (\$1,42 billion and \$15.4 bill	Cash and cash equivalents	\$ 325,717 \$	109,878
Agency CMBS, at fair value 1,754,740 2,850,717 Loans led for investments sold 1,353,252 14,202,815 Acceivable for investments sold	Non-Agency RMBS, at fair value (net of allowance for credit losses of \$167 thousand and \$0 thousand, respectively)	2,218,289	2,614,408
Receivable for investments ald fair value 13,533,252 14,292,815 Receivable for investments sold 2	Agency RMBS, at fair value	99,988	6,490,293
Receivable for investments sold 446,225 Accound interest receivable 86,727 116,428 Other assets 15,155 194,301 Other assets of the raisest of the rais	Agency CMBS, at fair value	1,754,740	2,850,717
Accrued interest receivable	Loans held for investment, at fair value	13,533,252	14,292,815
Other assets 75,155 194,301 Derivatives, at fair value, net 7 155 194,301 Total assets 10° 8 18,938.68 27,118ce Excentified debt. of lateralized by Non-Agency RMBS (\$228 million pledged as collateral, respectively) \$ 4,700,037 \$ 13,427,548 Securitized debt. collateralized by Non-Agency RMBS (\$228 million and \$598 million pledged as collateral, respectively) \$ 4,700,037 \$ 8,179,608 Securitized debt. collateralized by Non-Agency RMBS (\$228 million and \$598 million pledged as collateral, respectively) \$ 4,700,037 \$ 8,179,608 Securitized debt. at fair value, collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively) \$ 70,641 \$ 8,179,608 Long term debt 7 70,641 7 76,402 98,508 Long term debt 7 76,402 98,508 12,56,337 Accruent interest payable 7 76,402 98,508 20,508 Accruent interest payable 7 76,402 98,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 20,508 <th< td=""><td>Receivable for investments sold</td><td>_</td><td>446,225</td></th<>	Receivable for investments sold	_	446,225
Derivatives, at fair value, net	Accrued interest receivable	86,727	116,423
Total assets (1)	Other assets	75,155	194,301
Calibilities: Secure dinancing agreements (\$6.7 billion and \$15.4 billion pledged as collateral, respectively) \$ 4,700,037 \$ 13,427,545 \$ Securitized debt, collateralized by Non-Agency RMBS (\$528 million and \$598 million pledged as collateral, respectively) 117,904 133,557 \$ Securitized debt at fair value, collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively) 117,904 8,179,608 collateral, respectively) 70,641 — Payable for investments purchased 70,641 — Payable for investments purchased 70,642 76,362 76,	Derivatives, at fair value, net	_	3,611
Securid financing agreements (\$6.7 billion and \$15.4 billion pledged as collateral, respectively contained by the collateralized by Non-Agency RMBS (\$528 million and \$598 million pledged as collateral, respectively (\$117,904 133,557 collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively)	Total assets (1)	\$ 18,093,868 \$	27,118,671
Securitized debt, collateralized by Non-Agency RMBS (\$528 million and \$598 million pledged as collateral, respectively) \$117,904 \$133,557 Securitized debt at fair value, collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively) \$8,757,449 \$8,179,608 Long term debt 70,641 — Payable for investments purchased 614,583 1,256,337 Accrued interest payable 76,362 98,568 Accounts payable and other liabilities 76,362 98,568 Accounts payable and other liabilities 23,899 6,163 Total liabilities (f) \$ 14,397,326 \$ 23,165,378 Stockholders Equity: 8 158 \$ 58 Preferred Stock, par value of \$0.01 per share, 100,000,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) \$ 58 \$ 58 8.00% Series A cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) \$ 104 \$ 104 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) \$ 2,322 \$ 1,873 Common stock: par value \$0.01 per share; 500,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference)<	Liabilities:		
Sceuritized debt at fair value, collateralized by loans held for investment (\$12.4 billion and \$12.1 billion pledged as collateral, respectively) 8,757,449 8,179,608 Long term debt 70,641 — Payable for investments purchased 614,583 1,256,337 Accrued interest payable 36,451 63,600 Dividends payable and other liabilities 23,899 6,163 Accounts payable and other liabilities \$ 14,397,326 23,165,378 Total liabilities (1) \$ 14,397,326 23,165,378 Treferred Stock, par value of \$0.01 per share; 100,000,000 shares authorized: * 58 58 8.00% Series A cumulative redeemable: 5,800,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) 130 130 8.00% Series B cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 104 104 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 80 80 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 104 104 Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and	Secured financing agreements (\$6.7 billion and \$15.4 billion pledged as collateral, respectively)	\$ 4,700,037 \$	13,427,545
Collateral, respectively	Securitized debt, collateralized by Non-Agency RMBS (\$528 million and \$598 million pledged as collateral, respectively)	117,904	133,557
Payable for investments purchased 614,583 1,256,337 Accrued interest payable 36,451 63,600 Dividends payable 76,362 98,568 Accounts payable and other liabilities 23,899 6,163 Total liabilities (1) \$ 14,397,326 \$ 23,165,378 Stockholders' Equity: ************************************		8,757,449	8,179,608
Accrued interest payable 36,451 63,600 Dividends payable 76,362 98,568 Accounts payable and other liabilities 23,899 6,163 Total liabilities (1) \$ 14,397,326 23,165,378 Stockholders' Equity: Preferred Stock, par value of \$0.01 per share, 100,000,000 shares authorized: Preferred Stock, par value of \$0.01 per share, 100,000,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) \$ 58 58 8.00% Series A cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$325,000 liquidation preference) 130 130 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 80 80 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 3,734,659 <th< td=""><td>Long term debt</td><td>70,641</td><td>_</td></th<>	Long term debt	70,641	_
Dividends payable 76,362 98,568 Accounts payable and other liabilities 23,899 6,163 Total liabilities (1) \$ 14,397,326 \$ 23,165,378 Stockholders' Equity: ************************************	Payable for investments purchased	614,583	1,256,337
Accounts payable and other liabilities (1) \$ 14,397,326 \$ 23,165,378 \$ 150tal liabilities (1) \$ 14,397,326 \$ 14,3	Accrued interest payable	36,451	63,600
Total liabilities (1) \$ 14,397,326 \$ 23,165,378 Stockholders' Equity: Preferred Stock, par value of \$0.01 per share, 100,000,000 shares authorized: 8.00% Series A cumulative redeemable: 5,800,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) \$ 58 58 8.00% Series B cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$325,000 liquidation preference) 130 130 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 104 104 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively 2,322 1,873 Additional paid-in-capital 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity	Dividends payable	76,362	98,568
Stockholders' Equity: Preferred Stock, par value of \$0.01 per share, 100,000,000 shares authorized: 8.00% Series A cumulative redeemable: 5,800,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) \$ 58 \$ 58 8.00% Series B cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$325,000 liquidation preference) 130 130 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 104 104 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 8.00m Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively 2,322 1,873 Additional paid-in-capital 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity 3,696,542 3,953,293	Accounts payable and other liabilities	23,899	6,163
Preferred Stock, par value of \$0.01 per share, 100,000,000 shares authorized: 8.00% Series A cumulative redeemable: 5,800,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) 8.00% Series B cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$325,000 liquidation preference) 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issue	Total liabilities (1)	\$ 14,397,326 \$	23,165,378
8.00% Series A cumulative redeemable: 5,800,000 shares issued and outstanding, respectively (\$145,000 liquidation preference) 8.00% Series B cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$325,000 liquidation preference) 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% S	Stockholders' Equity:		
preference) 8.00% Series B cumulative redeemable: 13,000,000 shares issued and outstanding, respectively (\$325,000 liquidation preference) 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively Additional paid-in-capital 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293	Preferred Stock, par value of \$0.01 per share, 100,000,000 shares authorized:		
preference) 7.75% Series C cumulative redeemable: 10,400,000 shares issued and outstanding, respectively (\$260,000 liquidation preference) 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively Additional paid-in-capital Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders Total stockholders' equity \$ 3,696,542 \$ 3,953,293		\$ 58 \$	58
preference) 104 104 8.00% Series D cumulative redeemable: 8,000,000 shares issued and outstanding, respectively (\$200,000 liquidation preference) 80 80 Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively 2,322 1,873 Additional paid-in-capital 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293		130	130
preference) 80 80 Common stock: par value \$0.01 per share; 500,000,000 shares authorized, 232,190,087 and 187,226,081 shares issued and outstanding, respectively 2,322 1,873 Additional paid-in-capital 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293		104	104
outstanding, respectively 2,322 1,873 Additional paid-in-capital 4,517,819 4,275,963 Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293		80	80
Accumulated other comprehensive income 554,981 708,336 Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293		2,322	1,873
Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293	Additional paid-in-capital	4,517,819	4,275,963
Cumulative earnings 3,734,659 3,793,040 Cumulative distributions to stockholders (5,113,611) (4,826,291) Total stockholders' equity \$ 3,696,542 \$ 3,953,293	Accumulated other comprehensive income	554,981	708,336
Total stockholders' equity \$ 3,696,542 \$ 3,953,293	•	3,734,659	
	Cumulative distributions to stockholders	(5,113,611)	(4,826,291)
Total liabilities and stockholders' equity \$ 18,093,868 \$ 27,118,671	Total stockholders' equity	\$ 3,696,542 \$	3,953,293
	Total liabilities and stockholders' equity	\$ 18,093,868 \$	27,118,671

⁽¹⁾ The Company's consolidated statements of financial condition include assets of consolidated variable interest entities ("VIEs") that can only be used to settle obligations and liabilities of the VIE for which creditors do not have recourse to the primary beneficiary (Chimera Investment Corporation). As of September 30, 2020, and December 31, 2019, total assets of consolidated VIEs were \$12,795,729 and \$12,544,744, respectively, and total liabilities of consolidated VIEs were \$8,660,123 and \$8,064,235, respectively.

CHIMERA INVESTMENT CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS

(dollars in thousands, except share and per share data) (Unaudited)

		For the Quarters	For the Nine Months Ended		
	Sep	tember 30, 2020 Sep	tember 30, 2019 Sep	tember 30, 2020 Sep	tember 30, 2019
Net interest income:					
Interest income (1)	\$	247,905 \$	330,144 \$	794,094 \$	1,020,448
Interest expense (2)		124,557	188,551	395,897	589,611
Net interest income		123,348	141,593	398,197	430,837
Increase/(decrease) in provision for credit losses		(1,650)	_	167	_
Net other-than-temporary credit impairment losses		_	_	_	(4,853)
Other investment gains (losses):					
Net unrealized gains (losses) on derivatives		_	31,620	201,000	(189,865)
Realized gains (losses) on terminations of interest rate swaps		_	(148,114)	(463,966)	(351,372)
Net realized gains (losses) on derivatives		_	(20,178)	(41,086)	(37,151)
Net gains (losses) on derivatives		_	(136,672)	(304,052)	(578,388)
Net unrealized gains (losses) on financial instruments at fair value		260,766	130,825	(172,042)	522,386
Net realized gains (losses) on sales of investments		65,041	1,596	167,275	2,673
Gains (losses) on extinguishment of debt		(55,794)	_	(55,338)	(608)
Total other gains (losses)		270,013	(4,251)	(364,157)	(53,937)
Other expenses:					
Compensation and benefits		10,287	12,191	33,476	38,675
General and administrative expenses		6,811	6,528	19,050	18,569
Servicing fees		8,898	8,881	28,359	27,125
Transaction expenses		1,624	3,415	11,239	4,289
Total other expenses		27,620	31,015	92,124	88,658
Income (loss) before income taxes		367,391	106,327	(58,251)	283,389
Income taxes		62	1	130	156
Net income (loss)	\$	367,329 \$	106,326 \$	(58,381) \$	283,233
Dividends on preferred stock		18,438	18,438	55,313	54,267
Net income (loss) available to common shareholders	\$	348,891 \$	87,888 \$	(113,694)\$	228,966
Net income (loss) per share available to common shareholders:					
Basic	\$	1.50 \$	0.47 \$	(0.55)\$	1.22
Diluted	\$	1.32 \$	0.47 \$	(0.55) \$	1.22
Weighted average number of common shares outstanding:					
Basic		232,127,224	187,158,167	206,237,705	187,141,377
Diluted		265,346,359	188,440,171	206,237,705	188,331,109

⁽¹⁾ Includes interest income of consolidated VIEs of \$171,442 and \$192,622 for the quarters ended September 30, 2020 and 2019, respectively and \$515,250 and \$600,436 for the nine months ended September 30, 2020 and 2019, respectively.

⁽²⁾ Includes interest expense of consolidated VIEs of \$74,753 and \$82,234 for the quarters ended September 30, 2020 and 2019, respectively and \$210,198 and \$260,790 for the nine months ended September 30, 2020 and 2019, respectively.

CHIMERA INVESTMENT CORPORATION CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(dollars in thousands, except share and per share data) (Unaudited)

		For the Quarters Ended				For the Nine Months Ended		
	S	september 30, 2020	5	September 30, 2019	5	September 30, 2020	September 30, 2019	
Comprehensive income (loss):								
Net income (loss)	\$	367,329	\$	106,326	\$	(58,381) \$	283,233	
Other comprehensive income:								
Unrealized gains (losses) on available-for-sale securities, net (1)		40,470		29,980		(97,334)	115,198	
Reclassification adjustment for net losses included in net income for other-than-temporary credit impairment losses		_		_		_	4,853	
Reclassification adjustment for net realized losses (gains) included in net income		(22,999)	1	_		(56,021)	22,187	
Other comprehensive income (loss)		17,471		29,980		(153,355)	142,238	
Comprehensive income (loss) before preferred stock dividends	\$	384,800	\$	136,306	\$	(211,736) \$	425,471	
Dividends on preferred stock	\$	18,438	\$	18,438	\$	55,313 \$	54,267	
Comprehensive income (loss) available to common stock shareholders	\$	366,362	\$	117,868	\$	(267,049) \$	371,204	

⁽¹⁾ Quarter ended and nine months ended September 30, 2020 amounts includes \$150 thousand and \$15 million, respectively, of unrealized losses on AFS securities for which the Company has recognized an allowance for credit losses.

Core earnings

Core earnings is a non-GAAP measure and is defined as GAAP net income excluding unrealized gains on the aggregate portfolio, provision for credit losses, interest expense on long term debt, impairment losses, realized gains on sales of investments, realized gains or losses on futures, realized gains or losses on swap terminations, gain on deconsolidation, extinguishment of debt and expenses incurred in relation to securitizations. In addition, stock compensation expense charges incurred on awards to retirement eligible employees is reflected as an expense over a vesting period (36 months) rather than reported as an immediate expense.

As defined, core earnings include interest income and expense, as well as periodic cash settlements on interest rate swaps used to hedge interest rate risk and other expenses. Core earnings is inclusive of preferred dividend charges, compensation and benefits (adjusted for awards to retirement eligible employees), general and administrative expenses, servicing fees, as well as income tax expenses incurred during the period. Management believes that the presentation of core earnings provides investors with a useful measure but has important limitations. We believe core earnings as described above helps us evaluate our financial performance period over period without the impact of certain transactions but is of limited usefulness as an analytical tool. Therefore, core earnings should not be viewed in isolation and is not a substitute for net income or net income per basic share computed in accordance with GAAP. In addition, our methodology for calculating core earnings may differ from the methodologies employed by other REITs to calculate the same or similar supplemental performance measures, and accordingly, our reported core earnings may not be comparable to the core earnings reported by other REITs.

The following table provides GAAP measures of net income and net income per diluted share available to common stockholders for the periods presented and details with respect to reconciling the line items to core earnings and related per average diluted common share amounts. The Core earnings is presented on an adjusted dilutive shares basis. The adjusted dilutive shares used for core earnings is a non-GAAP measure which includes the GAAP dilutive shares of 265 million, adjusted for the dilutive effect of approximately 20 million shares on warrants issued in second quarter of 2020. We exclude the dilutive effect of the warrants as the warrant holders do not participate in dividends. Certain prior period amounts have been reclassified to conform to the current period's presentation.

	For the Quarters Ended							
	Septe	mber 30, 2020	June 30, 2020	March 31, 2020	December 31, 2019	September 30, 2019		
			(dollars in t	thousands, except per share	e data)			
GAAP Net income available to common stockholders	\$	348,891 \$	(73,393) \$	(389,193) \$	111,881 \$	\$ 87,888		
Adjustments:								
Interest expense on long term debt		1,495	4,391	_	_	_		
Increase (decrease) in provision for credit losses		(1,650)	(4,497)	6,314	_	_		
Net unrealized (gains) losses on derivatives		_	_	(201,000)	(83,656)	(31,620)		
Net unrealized (gains) losses on financial instruments at fair value		(260,766)	171,921	260,887	112,751	(130,825)		
Net realized (gains) losses on sales of investments		(65,041)	(26,380)	(75,854)	(17,687)	(1,596)		
(Gains) losses on extinguishment of debt		55,794	(459)	_	(9,926)	_		
Realized (gains) losses on terminations of interest rate swaps		_	_	463,966	8,353	148,114		
Net realized (gains) losses on Futures (1)		_	_	34,700	(8,229)	19,138		
Transaction expenses		1,624	4,710	4,906	6,639	3,415		
Stock Compensation expense for retirement eligible awards		(275)	(273)	1,189	(45)	(145)		
Core Earnings	\$	80,072 \$	76,020 \$	105,915 \$	120,081	94,369		
GAAP net income per diluted common share	\$	1.32 \$	(0.37) \$	(2.08) \$	0.59 \$	\$ 0.47		
Core earnings per adjusted diluted common share (2)	\$	0.33 \$	0.32 \$	0.56 \$	0.64 \$	\$ 0.50		

⁽¹⁾ Included in net realized gains (losses) on derivatives in the Consolidated Statements of Operations.

⁽²⁾ We note that core and taxable earnings will typically differ, and may materially differ, due to differences on realized gains and losses on investments and related hedges, credit loss recognition, timing differences in premium amortization, accretion of discounts, equity compensation and other items.

September 30, 2020

	at Period-End Admortiz		Weighted Average Weighted Average V Amortized Fair Value		Weighted Average Yield at Period-End ⁽¹⁾	
Non-Agency RMBS						
Senior	\$ 1,629,183 \$	51.33	81.81	4.5	% 16.5 %	
Subordinated	915,631	63.57	64.58	3.6	6.3 %	
Interest-only	6,056,933	4.33	4.85	1.5	% 16.8 %	
Agency RMBS						
Interest-only	1,343,378	9.24	7.44	1.9	% 1.5 %	
Agency CMBS						
Project loans	1,538,077	101.82	112.24	4.1	% 3.9 %	
Interest-only	1,383,665	1.89	2.06	0.7	% 7.9 %	

⁽¹⁾ Bond Equivalent Yield at period end.

n	ece)	m	he	r	3	1	2	N1	Q
v	CCC	ш	nc	71	J	1.	~	UΙ	,

		Principal or Notional Value at Period-End (dollars in thousands)			Weighted Average Fair Value	Weighted Avera Coupon	ge '	Weighted Average Yield at Period-End ⁽¹⁾	
Non-Agency RMBS									
Senior	\$	2,024,564 \$	52.98	\$	84.01	5.0	%	20.8 %	
Subordinated		876,592	63.15		71.25	3.7	%	6.9 %	
Interest-only		7,458,653	4.04		3.87	1.1	%	8.4 %	
Agency RMBS									
Pass-through		6,080,547	102.15		104.64	4.0	%	3.4 %	
Interest-only		1,539,941	9.06		8.29	1.6	%	4.0 %	
Agency CMBS									
Project loans		2,621,938	101.82		106.86	3.7	%	3.6 %	
Interest-only		1,817,246	2.81		2.70	0.7	%	4.7 %	

⁽¹⁾ Bond Equivalent Yield at period end.

At September 30, 2020 and December 31, 2019, the secured financing agreements collateralized by MBS and Loans held for investment had the following remaining maturities and borrowing rates.

September 30, 2020

December 31, 2019

			, = - = -							
	(dollars in thousands)									
	Principal	Weighted Average Borrowing Rates	Range of Borrowing Rates		Principal	Weighted Average Borrowing Rates	Range of Borrowing Rates			
Overnight	\$ _	NA	NA	\$	_	NA	NA			
1 to 29 days	1,610,030	0.58%	0.20% - 3.02%		9,709,387	2.26%	1.90% - 3.62%			
30 to 59 days	212,333	2.35%	1.85% - 2.55%		800,648	2.96%	2.15% - 3.52%			
60 to 89 days	14,626	1.83%	1.55% - 2.45%		608,520	3.00%	2.59% - 3.35%			
90 to 119 days	_	NA	NA		_	NA	NA			
120 to 180 days	606,072	4.23%	1.34% - 6.61%		809,077	3.38%	3.06% - 3.46%			
180 days to 1 year	1,004,318	6.02%	3.25% - 7.99%		580,886	3.42%	3.26% - 3.51%			
1 to 2 years	92,695	4.50%	4.50% - 4.50%		427,981	3.28%	3.19% - 3.30%			
2 to 3 years	395,829	7.00%	7.00% - 7.00%		_	NA	NA			
Greater than 3 years	764,134	3.84%	1.55% - 5.56%		491,046	3.20%	3.19% - 3.20%			
Total	\$ 4,700,037	3.44%	- -	\$	13,427,545	2.52%	- -			
				_			 -			

The following table summarizes certain characteristics of our portfolio at September 30, 2020 and December 31, 2019.

	Sep	tember 30, 2020	December 31, 2019	
Interest earning assets at period-end (1)	\$	17,606,269 \$	26,248,233	
Interest bearing liabilities at period-end	\$	13,646,031 \$	21,740,710	
GAAP Leverage at period-end		3.7:1	5.5:1	
GAAP Leverage at period-end (recourse)		1.3:1	3.4:1	
Portfolio Composition, at amortized cost				
Non-Agency RMBS		10.2 %	7.9 %	
Senior		5.1 %	4.5 %	
Subordinated		3.5 %	2.2 %	
Interest-only		1.6 %	1.2 %	
Agency RMBS		0.8 %	25.7 %	
Pass-through		—%	25.1 %	
Interest-only		0.8 %	0.6 %	
Agency CMBS		9.7 %	11.0 %	
Project loans		9.5 %	10.8 %	
Interest-only		0.2 %	0.2 %	
Loans held for investment		79.3 %	55.4 %	
Fixed-rate percentage of portfolio		94.9 %	95.9 %	
Adjustable-rate percentage of portfolio		5.1 %	4.1 %	

⁽¹⁾ Excludes cash and cash equivalents.

Economic Net Interest Income

Our "Economic net interest income" is a non-GAAP financial measure, that equals interest income, less interest expense and realized losses on our interest rate swaps are the periodic net settlement payments made or received. For the purpose of computing economic net interest income and ratios relating to cost of funds measures throughout this section, interest expense includes net payments on our interest rate swaps, which is presented as a part of Realized gains (losses) on derivatives in our Consolidated Statements of Operations and Comprehensive Income. Interest rate swaps are used to manage the increase in interest paid on repurchase agreements in a rising rate environment. Presenting the net contractual interest payments on interest payments with the interest paid on interest-bearing liabilities reflects our total contractual interest payments. We believe this presentation is useful to investors because it depicts the economic value of our investment strategy by showing actual interest expense and net interest income. Where indicated, interest expense, including interest payments on interest rate swaps, is referred to as economic interest expense. Where indicated, net interest income reflecting interest payments on interest rate swaps, is referred to as economic net interest income.

The following table reconciles the GAAP and non-GAAP measurements reflected in the Management's Discussion and Analysis of Financial Condition and Results of Operations.

	GAAP Interest Income	GAAP Interest Expense	Net Realized (Gains) Losses on Interest Rate Swaps	Interest Expense on Long Term Debt	Economic Interest Expense	GAAP Net Interest Income	Net Realized Gains (Losses) on Interest Rate Swaps	Other (1)	Economic Net Interest Income
For the Quarter Ended September 30, 2020	\$ 247,905	\$ 124,557 \$	_	\$ (1,495)\$	123,062	\$ 123,348	\$ - \$	1,487 \$	124,835
For the Quarter Ended June 30, 2020	\$ 245,922	\$ 129,256 \$	_	\$ (4,391) \$	124,865	\$ 116,666	\$ - \$	4,358 \$	121,024
For the Quarter Ended March 31, 2020	\$ 300,266	\$ 142,083 \$	6,385	s — s	148,468	\$ 158,183	\$ (6,385)\$	(1,266) \$	150,532
For the Quarter Ended December 31, 2019	\$ 340,662	\$ 169,203 \$	5,409	s — s	174,612	\$ 171,459	\$ (5,409)\$	(1,664)\$	164,386
For the Quarter Ended September 30, 2019	\$ 330,144	\$ 188,551 \$	963	s — \$	189,514	\$ 141,593	\$ (963) \$	(2,465) \$	138,165

⁽¹⁾ Primarily interest expense on Long term debt and interest income on cash and cash equivalents.

The table below shows our average earning assets held, interest earned on assets, yield on average interest earning assets, average debt balance, economic interest expense, economic average cost of funds, economic net interest income, and net interest rate spread for the periods presented.

	For the Quarter Ended							
	September 30, 2020 (dollars in thousands)				September 30, 2019 (dollars in thousands)			
	Average Balance	Interest	Average Yield/Cost		Average Balance	Interest	Average Yield/Cost	
Assets:								
Interest-earning assets (1):								
Agency RMBS	\$ 127,273 \$	495	1.6 %	\$	8,474,168 \$	68,984	3.3 %	
Agency CMBS	1,770,009	25,571	5.8 %		2,304,541	20,179	3.5 %	
Non-Agency RMBS	1,692,702	56,311	13.3 %		1,956,631	70,374	14.4 %	
Loans held for investment	12,943,898	165,520	5.1 %		12,017,663	168,142	5.6 %	
Total	\$ 16,533,882 \$	247,897	6.0 %	\$	24,753,003 \$	327,679	5.3 %	
Liabilities and stockholders' equity:				_				
Interest-bearing liabilities:								
Secured financing agreements collateralized by:								
Agency RMBS	\$ 76,755 \$	208	1.1 %	\$	7,948,235 \$	50,492	2.5 %	
Agency CMBS	1,680,566	1,141	0.3 %		2,160,190	14,097	2.6 %	
Non-Agency RMBS	1,171,542	17,495	6.0 %		1,376,214	12,916	3.8 %	
Loans held for investment	2,340,689	27,814	4.8 %		3,112,001	29,775	3.8 %	
Securitized debt	8,711,513	76,404	3.5 %		7,819,135	82,234	4.2 %	
Total	\$ 13,981,065 \$	123,062	3.5 %	\$	22,415,775 \$	189,514	3.4 %	
Economic net interest income/net interest rate spread	\$	124,835	2.5 %		\$	138,165	1.9 %	
Net interest-earning assets/net interest margin	\$ 2,552,817		3.0 %	\$	2,337,228		2.2 %	
Ratio of interest-earning assets to interest bearing liabilities	1.18	·			1.10			

⁽¹⁾ Interest-earning assets at amortized cost

The table below shows our Net Income and Economic Net Interest Income as a percentage of average stockholders' equity and Core Earnings as a percentage of average common stockholders' equity. Return on average equity is defined as our GAAP net income (loss) as a percentage of average equity. Average equity is defined as the average of our beginning and ending stockholders' equity balance for the period reported. Economic Net Interest Income and Core Earnings are non-GAAP measures as defined in previous sections.

	Return on Average Equity	Economic Net Interest Income/Average Equity *	Core Earnings/Average Common Equity	
		(Ratios have been annualize	d)	
For the Quarter Ended September 30, 2020	41.43 %	14.08 %	12.24 %	%
For the Quarter Ended June 30, 2020	(6.62)%	14.58 %	12.72 %	%
For the Quarter Ended March 31, 2020	(41.21)%	16.73 %	15.88 %	%
For the Quarter Ended December 31, 2019	13.12 %	16.55 %	15.78 %	%
For the Quarter Ended September 30, 2019	10.68 %	13.88 %	12.37 %	%

^{*} Includes effect of realized losses on interest rate swaps and excludes long term debt expense.

⁽²⁾ Interest includes net cash paid/received on swaps

The following table presents changes to Accretable Discount (net of premiums) as it pertains to our Non-Agency RMBS portfolio, excluding premiums on IOs, during the previous five quarters.

			or the Quarters Ended (dollars in thousands)		
Accretable Discount (Net of Premiums)	September 30, 2020	June 30, 2020	March 31, 2020	December 31, 2019	September 30, 2019
Balance, beginning of period	\$ 410,447 \$	438,232 \$	494,255 \$	494,780 \$	514,095
Accretion of discount	(20,045)	(22,508)	(24,784)	(44,342)	(33,256)
Purchases	2,096	_	(4,336)	(12,541)	(13,772)
Sales and deconsolidation	_	(23,425)	438	(786)	1,536
Transfers from/(to) credit reserve, net	30,483	18,148	(27,341)	57,144	26,177
Balance, end of period	\$ 422,981 \$	410,447 \$	438,232 \$	494,255 \$	494,780

Disclaimer

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, readers should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "target," "assume," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among other things, those described in our most recent Annual Report on Form 10-K, and any subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, under the caption "Risk Factors." Factors that could cause actual results to differ include, but are not limited to: our business and investment strategy; our ability to accurately forecast the payment of future dividends on our common and preferred stock, and the amount of such dividends; our ability to determine accurately the fair market value of our assets; availability of investment opportunities in real estate-related and other securities, including our valuation of potential opportunities that may arise as a result of current and future market dislocations; effect of the novel coronavirus (or COVID-19) pandemic on real estate market, financial markets and our Company, including the impact on the value, availability, financing and liquidity of mortgage assets; how COVID-19 may affect us, our operations and our personnel; our expected investments; changes in the value of our investments, including negative changes resulting in margin calls related to the financing of our assets; changes in interest rates and mortgage prepayment rates; prepayments of the mortgage and other loans underlying our mortgagebacked securities, or RMBS, or other asset-backed securities, or ABS; rates of default, delinquencies or decreased recovery rates on our investments; general volatility of the securities markets in which we invest; our ability to maintain existing financing arrangements and our ability to obtain future financing arrangements; our ability to effect our strategy to securitize residential mortgage loans; interest rate mismatches between our investments and our borrowings used to finance such purchases; effects of interest rate caps on our adjustable-rate investments; the degree to which our hedging strategies may or may not protect us from interest rate volatility; the impact of and changes to various government programs, including in response to COVID-19; impact of and changes in governmental regulations, tax law and rates, accounting guidance, and similar matters; market trends in our industry, interest rates, the debt securities markets or the general economy; estimates relating to our ability to make distributions to our stockholders in the future; our understanding of our competition; availability of qualified personnel; our ability to maintain our classification as a real estate investment trust, or, REIT, for U.S. federal income tax purposes; our ability to maintain our exemption from registration under the Investment Company Act of 1940, as amended, or 1940 Act; our expectations regarding materiality or significance; and the effectiveness of our disclosure controls and procedures.

Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Chimera does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Additional information concerning these and other risk factors is contained in Chimera's most recent filings with the Securities and Exchange Commission (SEC). All subsequent written and oral forward-looking statements concerning Chimera or matters attributable to Chimera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above.

Readers are advised that the financial information in this press release is based on company data available at the time of this presentation and, in certain circumstances, may not have been audited by the Company's independent auditors.





FINANCIAL SUPPLEMENT

3rd Quarter 2020

DISCLAIMER

This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, readers should not rely on these forward-looking statements as predictions of future events. Words such as "goal" "expect," "target," "assume," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among other things, those described in our most recent Annual Report on Form 10-K, and any subsequent Quarterly Reports on Form 10-Q and Current Report on Form 8-K, under the caption "Risk Factors." Factors that could cause actual results to differ include, but are not limited to:our business and investment strategy; our ability to accurately forecast the payment of future dividends on our common and preferred stock, and the amount of such dividends; our ability to determine accurately the fair market value of our assets; availability of investment opportunities in real estate-related and other securities, including our valuation of potential opportunities that may arise as a result of current and future market dislocations; effect of the novel coronavirus (or COVID-19) pandemic on real estate market, financial markets and our Company, including the impact on the value, availability, financing and liquidity of mortgage assets; how COVID-19 may affect us, our operations and our personnel; our expected investments; changes in the value of our investments, including negative changes resulting in margin calls related to the financing of our assets; changes in interest rates and mortgage prepayment rates; prepayments of the mortgage and other loans underlying our mortgage-backed securities, or RMBS, or other asset-backed securities, or ABS; rates of default, delinquencies or decreased recovery rates on our investments; general volatility of the securities markets in which we invest; our ability to maintain existing financing arrangements and our ability to obtain future financing arrangements; our ability to effect our strategy to securitize residential mortgage loans; interest rate mismatches between our investments and our borrowings used to finance such purchases; effects of interest rate caps on our adjustable-rate investments; the degree to which our hedging strategies may or may not protect us from interest rate volatility; the impact of and changes to various government programs, including in response to COVID-19; impact of and changes in governmental regulations, tax law and rates, accounting guidance, and similar matters; market trends in our industry, interest rates, the debt securities markets or the general economy; estimates relating to our ability to make distributions to our stockholders in the future; our understanding of our competition; availability of qualified personnel; our ability to maintain our classification as a real estate investment trust, or, REIT, for U.S. federal income tax purposes; our ability to maintain our exemption from registration under the Investment Company Act of 1940, as amended, or 1940 Act; our expectations regarding materiality or significance; and the effectiveness of our disclosure controls and procedures.

Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Chimera does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Additional information concerning these and other risk factors is contained in Chimera's most recent filings with the Securities and Exchange Commission (SEC). All subsequent written and oral forward-looking statements concerning Chimera or matters attributable to Chimera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above.

This presentation may include industry and market data obtained through research, surveys, and studies conducted by third parties and industry publications. We have not independently verified any such market and industry data from third-party sources. This presentation is provided for discussion purposes only and may not be relied upon as legal or investment advice, nor is it intended to be inclusive of all the risks and uncertainties that should be considered. This presentation does not constitute an offer to purchase or sell any securities, nor shall it be construed to be indicative of the terms of an offer that the parties or their respective affiliates would accept.

Readers are advised that the financial information in this presentation is based on company data available at the time of this presentation and, in certain circumstances, may not have been audited by the company's independent auditors.

CHIMERA INVESTMENT CORPORATION

Information is unaudited, estimated and subject to change.

PORTFOLIO COMPOSITION

Net Investment Analysis (2)

RESIDENTIAL		
MORTGAGE	AGENCY	TOTAL
CREDIT	PORTFOLIO	PORTFOLIO
PORTFOLIO		


GROSS ASSET YIELD:	6.1%	5.5%	6.0%
FINANCING COSTS ⁽³⁾	4.0%	0.3%	3.5%
NET INTEREST SPREAD:	2.1%	5.2%	2.5%
NET INTEREST MARGIN:	2.7%	5.2%	3.0%

All data as of September 30, 2020

- (1) Financing excludes unsettled trades.
- (2) Reflects third quarter 2020 average assets, yields, and spreads.
- (3) Includes the interest incurred on interest rate swaps.

Information is unaudited, estimated and subject to change.


92% of Chimera's equity capital is allocated to mortgage credit



GAAP ASSET ALLOCATION

Chimera added to the loan portfolio during the quarter


<u>September 30, 2020</u>



Based on fair value.

Information is unaudited, estimated and subject to change

December 31, 2019




Total Portfolio: \$26.2 billion



GAAP FINANCING SOURCES

3.7:1 total leverage and 1.3:1 recourse leverage⁽¹⁾ in Q3 compared to 5.5:1 total leverage and 3.4:1 recourse leverage⁽¹⁾ in Q4 2019

September 30, 2020




- Non-Agency Secured Financing, RMBS
- Agency Secured Financing, RMBS
- Agency Secured Financing, CMBS
- Non-Recourse Debt, Securitized RMBS and Loans (2)

Total Portfolio: \$13.6 billion

- (1) Leverage ratios as of September 30, 2020
- (2) Consists of tranches of RMBS and loan securitizations sold to third parties.

Information is unaudited, estimated and subject to change

December 31, 2019




- Non-Agency Secured Financing, RMBS
- Agency Secured Financing, RMBS
- Agency Secured Financing, CMBS
- Non-Recourse Debt, Securitized RMBS and Loans (2)

Total Portfolio: \$21.7 billion



NON-AGENCY FINANCING

Chimera continues to focus on longer term and non-markto-market financing for its non-agency portfolio



Data based on secured financing agreements outstanding as of September 30, 2020



CONSOLIDATED LOAN SECURITIZATIONS

VINTAGE	DEAL	TOTAL ORIGINAL FACE	TOTAL OF TRANCHES SOLD	TOTAL OF TRANCHES RETAINED	TOTAL REMAINING FACE	REMAINING FACE OF TRANCHES SOLD	REMAINING FACE OF TRANCHES RETAINED
2020	CIM 2020-R5	\$338,416	\$257,027	\$81,389	\$321,538	\$239,933	\$81,605
2020	CIM 2020-R4	276,316	207,237	69,079	270,441	201,262	69,179
2020	CIM 2020-R3	438,228	328,670	109,558	420,509	310,781	109,728
2020	CIM 2020-R2	492,347	351,926	140,421	468,501	393,398	75,103
2020	CIM 2020-R1	390,761	317,608	73,153	376,233	303,480	72,753
2019	CIM 2019-R5	315,039	252,224	62,815	280,229	217,581	62,648
2019	CIM 2019-R4	320,802	200,000	120,802	292,907	228,746	64,161
2019	CIM 2019-R3 ⁽¹⁾	342,633	291,237	51,396	299,091	247,671	51,420
2019	CIM 2019-R2	464,327	358,172	106,155	428,718	323,566	105,152
2019	CIM 2019-R1	371,762	297,409	74,353	334,376	260,399	73,977
2018	CIM 2018-NR1	257,548	_	257,548	158,226	, <u>-</u>	158,226
2018	CIM 2018-R6	478,251	334,775	143,476	362,504	220,924	141,580
2018	CIM 2018-R5	380,194	266,136	114,058	276,987	164,923	112,064
2018	CIM 2018-R4	387,222	271,056	116,166	298,624	183,948	114,676
2018	CIM 2018-R3	181,073	146,669	34,404	123,943	90,452	33,491
2018	CIM 2018-R2	380,292	266,204	114,088	266,667	152,982	113,685
2018	CIM 2018-R1	169,032	140,297	28,735	125,523	96,840	28,683
2017	CMLTI 2017-RP2	421,329	341,276	80,053	307,018	270,494	36,524
2017	CIM 2017-8	1,148,050	688,829	459,221	805,523	645,740	159,783
2017	CIM 2017-7	512,446	341,062	171,384	359,868	202,003	157,865
2017	CIM 2017-6	782,725	626,179	156,546	518,595	367,356	151,239
2017	CIM 2017-5	377,034	75,407	301,627	264,002	192,626	71,376
2017	CIM 2017-4	830,510	710,003	120,507	408,226	305,140	103,086
2017	CIM 2017-3	2,434,640	2,113,267	321,373	1,367,878	1,067,685	300,193
2017	CIM 2017-1	526,267	368,387	157,880	312,765	216,337	96,428
2016	CIM 2016-FRE1	185,811	115,165	70,646	110,365	47,996	62,369
2016	CIM 2016-3	1,746,084	1,478,933	267,151	886,343	652,718	233,625
2016	CIM 2016-2	1,762,177	1,492,563	269,614	892,717	654,277	238,440
2016	CIM 2016-1	1,499,341	1,266,898	232,443	755,885	556,109	199,776
2012	CSMC 2012-CIM3	329,886	305,804	24,082	64,057	51,752	12,305
2008	PHHMC 2008-CIM1	619,710	549,142	70,568	21,014	15,364	5,650
	TOTAL	\$19,160,253	\$14,759,562	\$4,400,691	\$12,179,273	\$8,882,483	\$3,296,790

All data as of September 30, 2020

\$ in thousands

(1) Accounted for as a secured borrowing

Information is unaudited, estimated and subject to change.





chimerareit.com